Browsing by Author Daud, Adil

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 15 of 15
Issue DateTitleAuthor(s)Citation
2014Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trialKefford, Richard (Rick); Boasberg, Peter; Chmielowski, Bartosz; Daud, Adil; Dronca, Roxana; Ebbinghaus, Scot; Elassaiss-Schaap, Jeroen; Gangadhar, Tara C.; Gergich, Kevin; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Iannone, Robert; Joseph, Richard W.; Joshua, Anthony M.; Kang, Peter; Li, Xiaoyun; Mateus, Christine; Patnaik, Amita; Postow, Michael; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Western Clinical School: Westmead Millennium InstituteAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, 9948, 2014,pp 1109-1117
2016Association of pembrolizumab with tumor response and survival among patients with advanced melanomaHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joshua, Anthony M.; Kefford, Richard F; Patnaik, Amita; Ribas, Antoni; Wolchok, Jedd D.; Northern Clinical School: SurgeryAssociation of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA: The Journal of the American Medical Association, vol.315, 15, 2016,pp 1600-1609
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2016Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with PembrolizumabHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard F.; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Northern Clinical School: SurgeryEvaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab, Journal of Clinical Oncology, vol.34, 13, 2016,pp 1510-1517
2016Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; Daud, Adil; et al, .; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, Kevin B; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreOverall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, Journal of Clinical Oncology, vol.34, 8, 2016,pp 871-878
2016Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; Daud, Adil; et al, .; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, Kevin B; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreOverall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, Journal of Clinical Oncology, vol.34, 8, 2016,pp 871-878
2017Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Carlino, Matteo; Long, Georgina; Arance, A; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lotem, Michal; McNeil, Catriona M.; Mortier, Laurent; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicinePembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, 10105, 2017,pp 1853-1862
2015Pembrolizumab versus ipilimumab in advanced melanomaCarlino, Matteo; Long, Georgina; Arance, Ana; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lorigan, Paul; Lotem, Michal; McNeil, Catriona; Mortier, Laurent; Neyns, Bart; Robert, Caroline; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentrePembrolizumab versus ipilimumab in advanced melanoma, The New England Journal of Medicine, vol.372, 26, 2015,pp 2521-2532
2016Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanomaHersey, Peter; Kefford, Richard (Rick); Daud, Adil; et al, Various; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Northern Clinical School: Surgery; Western Clinical School: Medicine (Westmead)Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma, Journal of Clinical Oncology, vol.34, 34, 2016,pp 4102-4109